norethindrone acetate ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
1963 51-98-9

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • aygestin
  • norlutate
  • norethindrone acetate
  • 19-Norethisterone acetate
  • norethisterone acetate
Acetate ester of norethindrone that is used as a long-term contraceptive (CONTRACEPTIVE AGENTS).
  • Molecular weight: 340.46
  • Formula: C22H28O3
  • CLOGP: 3.93
  • LIPINSKI: 0
  • HAC: 3
  • HDO: 0
  • TPSA: 43.37
  • ALOGS: -4.80
  • ROTB: 2

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 0.01 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 0 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 0.63 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD

Approvals:

DateAgencyCompanyOrphan
April 30, 1973 FDA WARNER CHILCOTT LLC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Vaginal haemorrhage 203.11 17.21 85 6813 27402 63454722
Heavy menstrual bleeding 151.81 17.21 61 6837 17712 63464412
Endometriosis 147.34 17.21 44 6854 5276 63476848
Pelvic pain 110.61 17.21 45 6853 13474 63468650
Hot flush 90.91 17.21 61 6837 51098 63431026
Hepatic adenoma 87.15 17.21 17 6881 326 63481798
Intermenstrual bleeding 73.91 17.21 29 6869 7897 63474227
Prostatic disorder 69.06 17.21 11 6887 59 63482065
Borderline serous tumour of ovary 49.91 17.21 7 6891 12 63482112
Purpura 48.44 17.21 24 6874 11361 63470763
Metaplasia 46.97 17.21 11 6887 513 63481611
Mood swings 42.94 17.21 26 6872 18222 63463902
Aplastic anaemia 40.20 17.21 20 6878 9549 63472575
Adnexal torsion 37.91 17.21 9 6889 445 63481679
Abdominal pain 37.64 17.21 92 6806 293364 63188760
Menstruation irregular 33.51 17.21 16 6882 6988 63475136
Dysmenorrhoea 31.71 17.21 13 6885 3960 63478164
Haemorrhage 31.60 17.21 36 6862 60986 63421138
Depression 29.99 17.21 66 6832 196426 63285698
Rash erythematous 28.94 17.21 29 6869 42481 63439643
Rash maculo-papular 27.90 17.21 25 6873 31871 63450253
Ovarian cyst 25.89 17.21 18 6880 15927 63466197
Menstrual disorder 25.00 17.21 12 6886 5301 63476823
Uterine leiomyoma 23.97 17.21 14 6884 9184 63472940
Rectal haemorrhage 23.83 17.21 28 6870 49002 63433122
Migraine 23.39 17.21 41 6857 103305 63378819
Pulmonary embolism 22.26 17.21 43 6855 116641 63365483
Anxiety 21.54 17.21 62 6836 217479 63264645
Hepatic rupture 21.19 17.21 4 6894 64 63482060
Peliosis hepatis 20.64 17.21 4 6894 74 63482050
Mood altered 20.17 17.21 15 6883 14728 63467396
Post viral fatigue syndrome 19.93 17.21 5 6893 312 63481812
Transfusion 19.75 17.21 15 6883 15202 63466922
Exposure to allergen 19.73 17.21 5 6893 325 63481799
Superior sagittal sinus thrombosis 19.56 17.21 6 6892 785 63481339
Menopausal symptoms 19.46 17.21 8 6890 2453 63479671
Melaena 19.36 17.21 20 6878 30345 63451779
Intracranial pressure increased 19.26 17.21 10 6888 5217 63476907
Pregnancy on oral contraceptive 17.97 17.21 6 6892 1031 63481093
Acne 17.93 17.21 17 6881 23276 63458848

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Vaginal haemorrhage 206.59 20.40 69 4700 21748 79717871
Metaplasia 133.80 20.40 24 4745 538 79739081
Heavy menstrual bleeding 119.52 20.40 41 4728 13970 79725649
Endometriosis 103.24 20.40 27 4742 3641 79735978
Prostatic disorder 96.37 20.40 23 4746 2137 79737482
Hepatic adenoma 77.53 20.40 14 4755 326 79739293
Pelvic pain 76.00 20.40 29 4740 13352 79726267
Hot flush 58.48 20.40 38 4731 54839 79684780
Borderline serous tumour of ovary 54.09 20.40 7 4762 12 79739607
Purpura 46.77 20.40 23 4746 19504 79720115
Adnexal torsion 44.79 20.40 9 4760 374 79739245
Intermenstrual bleeding 37.94 20.40 14 4755 5870 79733749
Aplastic anaemia 36.75 20.40 19 4750 17886 79721733
Borderline ovarian tumour 36.45 20.40 5 4764 16 79739603
Mood swings 32.13 20.40 18 4751 19862 79719757
Rash erythematous 27.98 20.40 25 4744 57744 79681875
Dysmenorrhoea 26.29 20.40 9 4760 3036 79736583
Menstruation irregular 25.34 20.40 10 4759 5026 79734593
Ovarian cyst 24.74 20.40 13 4756 12642 79726977
Rash maculo-papular 24.68 20.40 23 4746 56055 79683564
Abdominal pain 24.15 20.40 64 4705 389505 79350114
Transfusion 23.27 20.40 15 4754 21315 79718304
Genital haemorrhage 23.24 20.40 10 4759 6245 79733374
Uterine leiomyoma 22.96 20.40 10 4759 6433 79733186
Exposure to allergen 22.53 20.40 5 4764 336 79739283
Post viral fatigue syndrome 22.42 20.40 5 4764 344 79739275
Blood iron decreased 22.32 20.40 13 4756 15421 79724198
Rectal haemorrhage 22.13 20.40 25 4744 76275 79663344
Haemorrhage 21.71 20.40 27 4742 91091 79648528
Hepatic rupture 21.65 20.40 4 4765 106 79739513
Superior sagittal sinus thrombosis 21.35 20.40 6 4763 1057 79738562
Migraine 20.96 20.40 26 4743 87467 79652152
Anxiety 20.94 20.40 46 4723 248466 79491153
Peliosis hepatis 20.60 20.40 4 4765 139 79739480

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
FDA CS M0447349 Progesterone Congeners
FDA Chemical/Ingredient N0000011301 Progesterone Congeners
MeSH PA D003270 Contraceptive Agents
MeSH PA D003271 Contraceptive Agents, Female
MeSH PA D000080066 Contraceptive Agents, Hormonal
MeSH PA D012102 Reproductive Control Agents
MeSH PA D003278 Contraceptives, Oral, Hormonal
MeSH PA D003280 Contraceptives, Oral, Synthetic
CHEBI has role CHEBI:49326 synthetic oral contraceptives
CHEBI has role CHEBI:59826 progestins
FDA EPC N0000175602 Progestin

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Contraception indication 13197004
Dysfunctional uterine bleeding indication 19155002
Secondary physiologic amenorrhea indication 86030004
Acne vulgaris indication 88616000
Uterine fibroids indication 95315005 DOID:13223
Endometriosis indication 129103003
Amenorrhea off-label use 14302001 DOID:13938
Female hypogonadism syndrome off-label use 16041008
Polycystic ovaries off-label use 69878008
Dysmenorrhea off-label use 266599000
Abnormal uterine bleeding unrelated to menstrual cycle off-label use 312984006
Menorrhagia off-label use 386692008
Heart valve disorder contraindication 368009 DOID:4079
Hypercholesterolemia contraindication 13644009
Myocardial infarction contraindication 22298006 DOID:5844
Depressive disorder contraindication 35489007
Migraine contraindication 37796009 DOID:6364
Hypertensive disorder contraindication 38341003 DOID:10763
Disorder of gallbladder contraindication 39621005 DOID:0060262
Body fluid retention contraindication 43498006
Thrombosis of retinal vein contraindication 46085004
Chronic heart failure contraindication 48447003
Systemic lupus erythematosus contraindication 55464009 DOID:9074
Hyperlipidemia contraindication 55822004 DOID:1168
Benign mammary dysplasia contraindication 57993004
Obstructive hyperbilirubinemia contraindication 59848001
Thrombophlebitis contraindication 64156001 DOID:3875
Intermenstrual bleeding - irregular contraindication 64996003
Diabetes mellitus contraindication 73211009 DOID:9351
Hyperglycemia contraindication 80394007 DOID:4195
Epilepsy contraindication 84757009 DOID:1826
Kidney disease contraindication 90708001 DOID:557
Malignant neoplasm of liver contraindication 93870000 DOID:3571
Deep venous thrombosis contraindication 128053003
Liver function tests abnormal contraindication 166603001
Angina pectoris contraindication 194828000
Asthma contraindication 195967001 DOID:2841
Cerebrovascular accident contraindication 230690007
Pulmonary thromboembolism contraindication 233935004
Disease of liver contraindication 235856003 DOID:409
Cholestasis of pregnancy contraindication 235888006
Endometrial carcinoma contraindication 254878006 DOID:2871
Pregnancy, function contraindication 289908002
Hypertriglyceridemia contraindication 302870006
Functional visual loss contraindication 313165001
Malignant tumor of cervix contraindication 363354003 DOID:4362
Thromboembolic disorder contraindication 371039008
Cardiovascular event risk contraindication 395112001
Disorder of coronary artery contraindication 414024009
Obesity contraindication 414916001 DOID:9970
Estrogen receptor positive tumor contraindication 416053008
Porphyria contraindication 418470004
Optic disc edema contraindication 423341008 DOID:146
Hypertensive urgency contraindication 443482000
Carcinoma of female breast contraindication 447782002
Smokes tobacco daily contraindication 449868002
Major Surgery with Prolonged Post-Operative Immobilization contraindication
Nonspecific Abnormal Papanicolaou Smear of Cervix contraindication




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
1MG;0.5MG;40MG MYFEMBREE MYOVANT SCIENCES N214846 May 26, 2021 RX TABLET ORAL 9346822 Feb. 17, 2024 MANAGEMENT OF HEAVY MENSTRUAL BLEEDING ASSOCIATED WITH UTERINE LEIOMYOMAS (FIBROIDS) IN PREMENOPAUSAL WOMEN
0.01MG,0.01MG;1MG,N/A LO LOESTRIN FE APIL N022501 Oct. 21, 2010 RX TABLET ORAL 7704984 Feb. 2, 2029 LO LOESTRIN FE IS INDICATED FOR THE PREVENTION OF PREGNANCY IN WOMEN WHO ELECT TO USE ORAL CONTRACEPTIVES AS A METHOD OF CONTRACEPTION
0.01MG,0.01MG,N/A;1MG,N/A,N/A LO MINASTRIN FE APIL N204654 July 24, 2013 DISCN TABLET, CHEWABLE, TABLET ORAL 7704984 Feb. 2, 2029 PREVENTION OF PREGNANCY
1MG;0.5MG;40MG MYFEMBREE MYOVANT SCIENCES N214846 May 26, 2021 RX TABLET ORAL 11033551 Sept. 29, 2037 MANAGEMENT OF HEAVY MENSTRUAL BLEEDING ASSOCIATED WITH UTERINE LEIOMYOMAS (FIBROIDS) IN PREMENOPAUSAL WOMEN

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
1MG;0.5MG;40MG MYFEMBREE MYOVANT SCIENCES N214846 May 26, 2021 RX TABLET ORAL May 26, 2024 NEW PRODUCT
1MG;0.5MG;40MG MYFEMBREE MYOVANT SCIENCES N214846 May 26, 2021 RX TABLET ORAL Aug. 5, 2025 FOR THE MANAGEMENT OF MODERATE TO SEVERE PAIN ASSOCIATED WITH ENDOMETRIOSIS
1MG;0.5MG;40MG MYFEMBREE MYOVANT SCIENCES N214846 May 26, 2021 RX TABLET ORAL Dec. 18, 2025 NEW CHEMICAL ENTITY
1MG;0.5MG;40MG MYFEMBREE MYOVANT SCIENCES N214846 May 26, 2021 RX TABLET ORAL Jan. 27, 2026 INFORMATION ADDED TO THE LABELING TO DESCRIBE THE RESULTS OF MVT-601-035

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Progesterone receptor Nuclear hormone receptor AGONIST ED50 11.26 WOMBAT-PK CHEMBL
Sodium-dependent serotonin transporter Transporter Ki 5.62 CHEMBL
Glucocorticoid receptor Nuclear hormone receptor Ki 6.53 DRUG MATRIX
Estrogen receptor Nuclear hormone receptor Ki 6.64 CHEMBL
Androgen receptor Nuclear hormone receptor IC50 7.12 WOMBAT-PK
Cytochrome P450 2C19 Enzyme IC50 6.10 DRUG MATRIX
Sex hormone-binding globulin Secreted Kd 7.97 CHEMBL
Progesterone receptor Transcription factor Ki 8.44 DRUG MATRIX
Androgen receptor Transcription factor Ki 7.15 DRUG MATRIX

External reference:

IDSource
D00953 KEGG_DRUG
4018495 VANDF
4018496 VANDF
C0068980 UMLSCUI
CHEBI:7628 CHEBI
CHEBI:7627 CHEBI
CHEMBL1201146 ChEMBL_ID
CHEMBL1162 ChEMBL_ID
D000077563 MESH_DESCRIPTOR_UI
5832 PUBCHEM_CID
9S44LIC7OJ UNII
DB00717 DRUGBANK_ID
215496 RXNORM
182290 MMSL
2712 MMSL
41718 MMSL
5187 MMSL
5188 MMSL
d00555 MMSL
001298 NDDF
001299 NDDF
001326 NDDF
005925 NDDF
126102009 SNOMEDCT_US
126104005 SNOMEDCT_US
63758001 SNOMEDCT_US
C0028356 UMLSCUI
687 INN_ID
6230 PUBCHEM_CID
D009640 MESH_DESCRIPTOR_UI

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Jinteli HUMAN PRESCRIPTION DRUG LABEL 2 0093-3122 TABLET 1 mg ORAL ANDA 29 sections
Mimvey HUMAN PRESCRIPTION DRUG LABEL 2 0093-5455 TABLET, FILM COATED 0.50 mg ORAL ANDA 30 sections
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL HUMAN PRESCRIPTION DRUG LABEL 2 0378-7274 TABLET 1.50 mg ORAL ANDA 15 sections
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL HUMAN PRESCRIPTION DRUG LABEL 2 0378-7274 TABLET 1.50 mg ORAL ANDA 15 sections
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL HUMAN PRESCRIPTION DRUG LABEL 2 0378-7280 TABLET 1 mg ORAL ANDA 15 sections
Norethindrone Acetate HUMAN PRESCRIPTION DRUG LABEL 1 0378-7291 TABLET 5 mg ORAL ANDA 12 sections
ESTRADIOL AND NORETHINDRONE ACETATE HUMAN PRESCRIPTION DRUG LABEL 2 0378-7294 TABLET 0.10 mg ORAL ANDA 26 sections
ESTRADIOL AND NORETHINDRONE ACETATE HUMAN PRESCRIPTION DRUG LABEL 2 0378-7295 TABLET 0.50 mg ORAL ANDA 26 sections
femhrt HUMAN PRESCRIPTION DRUG LABEL 2 0430-0145 TABLET 0.50 mg ORAL NDA 33 sections
Norethindrone Acetate HUMAN PRESCRIPTION DRUG LABEL 1 0555-0211 TABLET 5 mg ORAL ANDA 20 sections
Junel21 Day HUMAN PRESCRIPTION DRUG LABEL 2 0555-9025 TABLET 1 mg ORAL ANDA 15 sections
Junel21 Day HUMAN PRESCRIPTION DRUG LABEL 2 0555-9025 TABLET 1 mg ORAL ANDA 15 sections
Junel21 Day HUMAN PRESCRIPTION DRUG LABEL 2 0555-9025 TABLET 1 mg ORAL ANDA 15 sections
Junel21 Day HUMAN PRESCRIPTION DRUG LABEL 2 0555-9027 TABLET 1.50 mg ORAL ANDA 15 sections
Junel21 Day HUMAN PRESCRIPTION DRUG LABEL 2 0555-9027 TABLET 1.50 mg ORAL ANDA 15 sections
Junel21 Day HUMAN PRESCRIPTION DRUG LABEL 2 0555-9027 TABLET 1.50 mg ORAL ANDA 15 sections
Norethindrone acetate Human Prescription Drug Label 1 16571-658 TABLET 5 mg ORAL ANDA 19 sections
Norethindrone Acetate HUMAN PRESCRIPTION DRUG LABEL 1 42291-650 TABLET 5 mg ORAL ANDA 12 sections
Norethindrone acetate Human Prescription Drug Label 1 50742-267 TABLET 5 mg ORAL ANDA 20 sections
Estradiol and Norethindrone Acetate HUMAN PRESCRIPTION DRUG LABEL 2 50742-657 TABLET 0.50 mg ORAL ANDA 29 sections
Estradiol and Norethindrone Acetate HUMAN PRESCRIPTION DRUG LABEL 2 50742-657 TABLET 0.50 mg ORAL ANDA 29 sections
Estradiol and Norethindrone Acetate HUMAN PRESCRIPTION DRUG LABEL 2 50742-658 TABLET 0.10 mg ORAL ANDA 29 sections
Estradiol and Norethindrone Acetate HUMAN PRESCRIPTION DRUG LABEL 2 50742-658 TABLET 0.10 mg ORAL ANDA 29 sections
Loestrin21 Day HUMAN PRESCRIPTION DRUG LABEL 2 51285-127 TABLET 1.50 mg ORAL ANDA 15 sections
Loestrin21 Day HUMAN PRESCRIPTION DRUG LABEL 2 51285-127 TABLET 1.50 mg ORAL ANDA 15 sections
Loestrin21 Day HUMAN PRESCRIPTION DRUG LABEL 2 51285-131 TABLET 1 mg ORAL ANDA 15 sections
Loestrin21 Day HUMAN PRESCRIPTION DRUG LABEL 2 51285-131 TABLET 1 mg ORAL ANDA 15 sections
Aygestin HUMAN PRESCRIPTION DRUG LABEL 1 51285-424 TABLET 5 mg ORAL ANDA 20 sections
MICROGESTIN 1/20 HUMAN PRESCRIPTION DRUG LABEL 2 51862-007 TABLET 1 mg ORAL NDA authorized generic 21 sections
MICROGESTIN 1/20 HUMAN PRESCRIPTION DRUG LABEL 2 51862-007 TABLET 1 mg ORAL NDA authorized generic 21 sections